Cellectis SA (NASDAQ:CLLS) — Market Cap & Net Worth
Market Cap & Net Worth: Cellectis SA (CLLS)
Cellectis SA (NASDAQ:CLLS) has a market capitalization of $286.73 Million ($286.73 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15147 globally and #3412 in its home market, demonstrating a 1.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellectis SA's stock price $3.95 by its total outstanding shares 72590994 (72.59 Million). Analyse CLLS cash generation efficiency to see how efficiently the company converts income to cash.
Cellectis SA Market Cap History: 2015 to 2026
Cellectis SA's market capitalization history from 2015 to 2026. Data shows change from $2.25 Billion to $286.73 Million (-16.55% CAGR).
Index Memberships
Cellectis SA is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #405 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1451 of 3165 |
Weight: Cellectis SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellectis SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellectis SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.80x
Cellectis SA's market cap is 4.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.23 Billion | $42.58 Million | -$63.92 Million | 28.89x | N/A |
| 2017 | $2.12 Billion | $25.19 Million | -$99.37 Million | 84.01x | N/A |
| 2018 | $1.21 Billion | $12.73 Million | -$78.69 Million | 94.94x | N/A |
| 2019 | $1.24 Billion | $15.19 Million | -$90.69 Million | 81.81x | N/A |
| 2020 | $1.96 Billion | $73.95 Million | -$72.57 Million | 26.56x | N/A |
| 2021 | $589.44 Million | $73.95 Million | -$86.28 Million | 7.97x | N/A |
| 2022 | $152.44 Million | $19.17 Million | -$98.69 Million | 7.95x | N/A |
| 2023 | $223.58 Million | $755.00K | -$101.06 Million | 296.13x | N/A |
| 2024 | $130.66 Million | $41.51 Million | -$36.76 Million | 3.15x | N/A |
| 2025 | $351.34 Million | $73.17 Million | -$67.80 Million | 4.80x | N/A |
Competitor Companies of CLLS by Market Capitalization
Companies near Cellectis SA in the global market cap rankings as of May 4, 2026.
Key companies related to Cellectis SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cellectis SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Cellectis SA's market cap moved from $2.25 Billion to $ 286.73 Million, with a yearly change of -16.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $286.73 Million | -18.39% |
| 2025 | $351.34 Million | +168.89% |
| 2024 | $130.66 Million | -41.56% |
| 2023 | $223.58 Million | +46.67% |
| 2022 | $152.44 Million | -74.14% |
| 2021 | $589.44 Million | -69.99% |
| 2020 | $1.96 Billion | +58.06% |
| 2019 | $1.24 Billion | +2.82% |
| 2018 | $1.21 Billion | -42.88% |
| 2017 | $2.12 Billion | +71.98% |
| 2016 | $1.23 Billion | -45.38% |
| 2015 | $2.25 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Cellectis SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $286.73 Million USD |
| MoneyControl | $286.73 Million USD |
| MarketWatch | $286.73 Million USD |
| marketcap.company | $286.73 Million USD |
| Reuters | $286.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more